PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation
Treadmill vs Cycling in Parkinson´s Disease Rehabilitation. Non-pharmacological, Randomized, Blind Rater, Clinical Trial for the Definition of the Most Effective Model in Gait Reeducation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sabela Novo, MD
- Phone Number: +34 911 91 60 00
- Email: sabela.novo@salud.madrid.org
Study Locations
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Recruiting
- Hospital Universitario Puerta De Hierro
-
Contact:
- Sabela Novo Ponte, MD
- Email: sabela.novo@salud.madrid.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is diagnosed with idiopathic Parkinson's disease according to criteria from the United Kingdom Parkinson's Disease Society Brain Bank (UK-PDSBB)
- H&Y less than or equal to 2
- Stable drug treatment in the six weeks prior to the start of training and during the study.
- Signature of informed consent.
Exclusion Criteria:
- Diagnosis of other neuro-degenerative disease
- Cardiovascular disease or other systemic condition that contraindicates the moderate physical exercise
- Need for ambulation support
- Frequent freezing of gait events.
- Mni- Mental State Examination (MMSE) <26
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: treadmill training
Three training sessions per week for two months of treadmill.
The intensity of exercise is monitored through the heart rate (HR).
Patients ought to maintain a HR between 40 and 50% of the reserve HR
|
treadmill training and cycling training in equal intensity exercise.
|
|
ACTIVE_COMPARATOR: Cycling
Three training sessions per week for two months of cycling.
The intensity of exercise is monitored through the heart rate (HR).
Patients ought to maintain a HR between 40 and 50% of the reserve HR
|
treadmill training and cycling training in equal intensity exercise.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in step length after treadmill training or cycling.
Time Frame: Ten months
|
Highlight changes in the length of the step after training in treadmill or cycling in patients with Parkinson´s disease.
|
Ten months
|
|
Changes in step length after treadmill training. Discussion of its specificity to Parkinson´s disease
Time Frame: Ten months
|
A description of step length and cadence for different velocities of gait after treadmill training.
|
Ten months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rating Scale for Gait Evaluation in Parkinson's disease ( RSGE- PD scale )
Time Frame: Ten months
|
Gait status through the RSGE-PD Scale before and after the intervention.
|
Ten months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Movement Disorders Society- Unified Parkinson´s Disease Rating Scale II. (MDS-UPDRS II)
Time Frame: Ten months
|
Motor functional status through the MDS-UPDRS II Scale before and after the intervention.
|
Ten months
|
|
MDS-UPDRS III
Time Frame: Ten months
|
Motor examination status through the MDS UPDRS III Scale before and after the intervention
|
Ten months
|
|
The 39-item Parkinson´s Disease Questionnaire (PDQ-39)
Time Frame: Ten months
|
Quality of life through the PDQ 39 Scale before and after the intervention.,
|
Ten months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P.I.: 154/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.